Table 5 Relationship between the incidence of the primary endpoint and the TyG index expressed as a categorical variable

TyG index tertiles

 T1

Reference

Reference

 T2

1.74 (1.17–2.57)

1.60 (1.06–2.40)

 T3

2.27 (1.56–3.32)

2.15 (1.44–3.22)

 Age

1.01 (0.99–1.02)

0.99 (0.97–1.004)

 BMI

0.98 (0.94–1.02)

0.97 (0.92–1.01)

 DBP

0.98 (0.96–0.99)

0.99 (0.97–1.00)

 HDL-C

0.98 (0.96–1.00)

0.98 (0.96–1.00)

 Glycosylated haemoglobin

1.05 (0.94–1.18)

0.93 (0.82–1.06)

 Male sex

0.92 (0.67–1.26)

0.68 (0.44–1.04)

 Current smoking

0.94 (0.70–1.27)

1.02 (0.71–1.46)

 Daily drinking

1.01 (0.62–1.65)

1.30 (0.77–2.18)

 Previous MI

1.52 (1.11–2.09)

0.88 (0.61–1.27)

 Past PCI

1.79 (1.33–2.41)

1.72 (1.17–2.53)

 PAD

2.82 (2.05–3.87)

2.22 (1.52–3.24)

 CKD

1.70 (1.07–2.70)

1.46 (0.85–2.52)

 Cardiac failure

2.27 (1.52–3.40)

1.59 (1.00–2.52)

 Insulin at discharge

1.39 (1.04–1.87)

0.95 (0.67–1.36)

 Metformin at discharge

1.12 (0.76–1.63)

1.08 (0.72–1.62)

 Alpha-glucosidase inhibitors at discharge

0.89 (0.66–1.21)

0.76 (0.55–1.06)

 Sulfonylurea at discharge

0.89 (0.64–1.26)

0.95 (0.65–1.38)

 Dipeptidyl peptidase 4 inhibitors at discharge

1.34 (0.50–3.60)

1.24 (0.44–3.48)

CAD severity

 One-vessel disease

Reference

Reference

 Two-vessel disease

2.08 (0.87–5.01)

1.30 (0.52–3.24)

 LM/three-vessel disease

4.32 (1.91–9.76)

2.16 (0.91–5.13)

 Lesions > 20 mm long

2.07 (1.51–2.84)

1.59 (1.13–2.23)

 DCB use

2.07 (1.33–3.23)

1.23 (0.73–2.08)

 Complete revascularization

0.46 (0.35–0.62)

0.63 (0.46–0.86)